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Type I and type III interferons (IFNs) activate similar antiviral transcriptional programs, but the type I IFN
response is more inflammatory. In this issue of Immunity, Forero et al. find that selective induction of the
transcription factor IRF1 promotes proinflammatory chemokine expression downstream of type I IFN
signaling.
1Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USAType I interferons (IFN-a, IFN-b) and type
III interferons (IFN-l) are antiviral cyto-
kines that activate similar signaling
pathways and induce overlapping tran-
scriptional responses but signal through
distinct receptors (Lazear et al., 2019; Ye
et al., 2019). Although the set of IFN-stim-
ulated genes (ISGs) induced by type I and
type III IFNs is largely similar, spatiotem-
poral differences in these responses
lead to distinct physiological functions
for the two IFN subtypes. Overall, the
type III IFN response has lower potency
and slower kinetics compared to the
type I IFN response, and the type III IFN
response predominates at epithelial sur-
faces, such as the respiratory and gastro-
intestinal tracts, supporting a model in
which the type III IFN response provides
front-line protection at sites in frequent
contact with commensal and pathogenic
microbes. Importantly, type III IFN
signaling activates an antiviral response
without the inflammatory pathology eli-
cited by type I IFN signaling (Broggi
et al., 2017; Galani et al., 2017). However,
given the similarities in the signaling cas-
cades and transcriptional programs acti-
vated downstream of type I and type III
IFN signaling, the mechanisms underlying
their distinct kinetics and immunoregula-
tory effects have remained unclear. In
this issue of Immunity, Forero et al.
(2019) show that, despite significant over-
all similarity in their transcriptional re-
sponses, induction of the transcription
factor IRF1 distinguishes the type I and
type III IFN responses, leading to the pro-
duction of proinflammatory chemokines
and leukocyte recruitment specifically in
response to type I IFN signaling.
To begin this work, Forero and col-
leagues showed that in cells treated with
recombinant IFN-b or IFN-l, the tran-
scriptional and antiviral response inducedby type III IFNs was less potent and had
slower kinetics compared to the type I
IFN response, as expected from prior
studies. However, they noted that
although the set of ISGs induced by
IFN-b and IFN-l was largely identical, a
notable exception was the chemokines
CXCL9, CXCL10, and CXCL11, which
were induced exclusively by IFN-b, but
not IFN-l. These chemokines recruit
CXCR3-expressing leukocytes, including
T cells, natural killer (NK) cells, and inflam-
matory monocytes, so avoiding their
induction could explain the minimal in-
flammatory response elicited by type III
IFNs. Indeed, when the authors adminis-
tered IFN-b or IFN-l to mice intranasally,
only IFN-b induced Cxcl10 expression
and leukocyte recruitment in the lungs.
Altogether, these observations support
prior studies showing that IFN-l is less
inflammatory than IFN-b, but which
signaling pathways account for this
distinct response?
CXCR3 ligands can be induced down-
stream of IFN signaling following binding
of IFN-regulatory factor (IRF) transcription
factors to promoters containing IFN-stim-
ulated response elements (ISREs). Thus,
Forero and colleagues next examined
IRF induction following treatment with re-
combinant IFN-b and IFN-l in PH5CH8
human hepatocytes. As expected, IRF7
and IRF9 levels increased following treat-
ment with either IFN. In contrast, IRF1was
induced exclusively by IFN-b treatment,
not IFN-l. The authors showed a similar
effect in A549 human airway epithelial
cells, demonstrating that this effect is
not specific to hepatocytes. Since IRF1
induces the expression of antiviral and in-
flammatory genes, including CXCL10 and
other proinflammatory chemokines, a
lack of IRF1 induction provides a plausible
mechanism for the diminished inflamma-tory response induced by IFN-l com-
pared to IFN-b. Another recent study
showed that basal IRF1 expression con-
tributes to an intrinsic antiviral response
in hepatocytes (Yamane et al., 2019), sug-
gesting that higher levels of IRF1 expres-
sion, such as that induced following viral
infection and IFN-b signaling, are needed
to stimulate leukocyte recruitment and
inflammation.
Since the canonical signaling pathways
activated by type I and type III IFNs are
identical (Figure 1), what allows IRF1 to
be induced selectively in response to
type I IFNs? Using RNA interference and
gene deletion approaches, the authors
found that STAT1 and STAT2 are both
required for IRF1 induction following
IFN-b treatment. However, only STAT1
homodimers bound the IRF1 promoter,
leading the authors to conclude that
STAT2 deficiency diminished STAT1
activation, thereby transiently diminishing
IRF1 induction. RNA-seq analyses of
IRF1-deficient and wild-type cells
following IFN-b treatment revealed that
IRF1 is required for induction of CXCL10,
CIITA, and TNFSF10, as well as genes
involved in coagulation and tissue repair.
Furthermore, expression of the IFNAR in-
hibitor USP18 required IRF1 while IRF1-
deficient cells exhibited a sustained anti-
viral response, suggesting a role for IRF1
in negative regulation of the type I IFN
response. Altogether, these findings sug-
gest a mechanism by which type III IFNs
can induce a protective antiviral response
without eliciting damaging inflammation.
The ability of IFN-b to induce specific
ISGs via STAT1 homodimers that are not
produced following IFN-l signaling high-
lights the contribution of non-canonical
signaling pathways to the overall IFN
response (Figure 1). While the canonical
pathway of JAK1- and TYK2-mediated
Figure 1. Type I and Type III IFN Signaling Pathways
Type I interferons (IFN-a, IFN-b) bind to a heterodimeric receptor comprised of IFNAR1 and IFNAR2 whereas type III interferons (IFN-l) bind to a distinct receptor
comprised of IFNLR1 and IL10Rb. In canonical IFN signaling, IFN binding activates receptor-associated kinases JAK1 and TYK2, which phosphorylate STAT1
and STAT2. Phosphorylated STAT1 and STAT2 associate with IRF9 to form a transcription factor that activates the expression of hundreds of IFN-stimulated
genes (ISGs). ISGs act by a variety of mechanisms to inhibit viral replication and exert immunomodulatory functions. In addition to the canonical pathway, type I
and type III IFNs can activate additional signaling pathways. Type I IFN can induce STAT1 homodimer formation, which leads to the induction of the transcription
factor IRF1, expression of chemokines, and inflammation. Forero and colleagues showed that type III IFN does not induce IRF1, whichmay explain the diminished
inflammatory response elicited by type III IFN. However, elevated IFNLR1 expression enabled IFN-l-mediated IRF1 induction. Type I and type III IFNs also can
activate additional STATs, including STAT3 and STAT5. Type III IFN can activate the kinase JAK2 instead of TYK2. Both type I and type III IFNs also activate other
kinase signaling pathways, including PI3K, AKT, andMAPK.While the canonical signaling pathway requires the production of ISG proteins tomediate the antiviral
response, other protective effects of IFN signaling are translation independent, including tightening cell junctions and inhibiting neutrophil degranulation. Since
the canonical signaling pathway is shared between type I and type III IFNs, the relative contributions of non-canonical signaling pathways (particularly in a cell-
type-dependent manner) may underlie biological differences in type I versus type III IFN responses.activation of STAT1/STAT2 heterodimers 
likely drives the majority of ISG expres-
sion, it has long been recognized that 
IFN signaling also activates additional 
signaling pathways beyond those typi-
cally depicted in signaling pathway dia-
grams; differences in these non-canonical 
pathways may contribute to the distinct 
biological effects of type I and type III 
IFN (Lazear et al., 2019; Platanias, 2005; 
Ye et al., 2019). For example, IFN-l can 
signal via JAK2, rather than TYK2, but 
IFN-b does not (Broggi et al., 2017; Ye 
et al., 2019). Other non-canonical path-
ways include activation of other STATs 
(STAT1 homodimers, STAT3, STAT5) as 
well as MAPK, AKT, and PI3K signaling 
pathways. Studies in intestinal organoid 
cultures found that the antiviral responseinduced by IFN-l, but not IFN-b, was
blocked by MAPK inhibitors, suggesting
differential effects of STAT-independent
signaling pathways (Lazear et al., 2019;
Ye et al., 2019). Indeed, Forero and col-
leagues observed an IFN-l-specific acti-
vation of the MAPK MKNK1, as well as
the tyrosine kinase MERTK. Other STAT-
independent IFN activities include inhibi-
tion of neutrophil degranulation and tight-
ening of cell-cell junctions in blood-brain
barrier endothelial cells, both of which
occur in a translation-independentmanner
(Broggi et al., 2017; Lazear et al., 2015).
Although the canonical type I and type III
IFN signaling pathways are identical, their
relative activation of non-canonical
signalingpathwaysmay represent amech-
anism for exerting distinct physiologic ef-fects. This could be especially pronounced
in particular cell types or disease states
where the relative contributions of non-ca-
nonical signaling pathways may vary.
A key distinction between the type I
and type III IFN responses is the distribu-
tion of receptor expression: IFNLR1 is ex-
pressed preferentially on epithelial cells
and some leukocytes (such as neutro-
phils), whereas IFNAR1 and IFNAR2 are
ubiquitously expressed (Ye et al., 2019).
Thus, IFNLR1 availability is a key determi-
nant of the type III IFN response. Since the
type III IFN response is less potent than
that of type I IFNs, Forero and colleagues
asked if IFNLR1 overexpression could
enable IRF1 induction by IFN-l. Indeed,
overexpressing IFNLR1 enabled IFN-l-
mediated IRF1 induction and STAT1
activation equivalent to the levels 
achieved following IFN-b treatment. 
Accordingly, CXCL10 was induced in 
IFNLR-overexpressing cells, and expres-
sion of ISGs such as ISG15 and MX1 also 
increased. These findings indicate that 
the reduced potency and lack of 
proinflammatory chemokine induction 
associated with the type III IFN response 
are threshold dependent and can be over-
come by elevated receptor expression. It 
will be interesting to determine whether 
there are specific cells or tissues in which 
endogenous IFNLR1 expression reaches 
the threshold required for IFN-l-mediated 
induction of IRF1 and induction of inflam-
matory chemokines. Notably, the authors 
found that in intestinal organoids, which 
are especially responsive to type III IFN, 
IFN-l treatment did induce IRF1 expres-
sion, albeit at lower levels than that 
induced by IFN-b. In addition to cell-type-
specific effects, there may be ge-netic, 
autoimmune, or infectious disease states 
that feature elevated IFNLR1 expression, 
which could potentiate IRF1 induction 
and an inflammatory response. However, 
the blunted inflammatory response 
characteristic of type III IFNs is best 
described in the lungs and gut, which are 
tissues with high IFNLR1 expression, 
suggesting that this model is relevant at 
physiological levels of IFNLR1. Forero and 
colleagues found no increase in IFNLR1 
expression following treatment with 
poly(I:C) or TNFa or after infection with 
Sendai virus or influenza A virus, implying 
that expression of IFNLR1 is not generally 
increased in response toinfection. However, other studies have
shown increased expression of IFNLR1
on neutrophils following fungal infection
(Espinosa et al., 2017) or on bone-
marrow-derived dendritic cells following
influenza A virus infection (Hemann
et al., 2019), suggesting that under some
circumstances increased IFNLR1 expres-
sion could potentiate IRF1 induction and
inflammatory responses.
Altogether, the study by Forero and col-
leagues provides mechanistic insight into
the observation that the antiviral response
induced by type III IFNs is less inflamma-
tory than the type I IFN response, which
may inform strategies to target these path-
ways therapeutically. Since limited IFNLR1
expression underpinned the lack of IRF1-
mediated chemokine induction by IFN-l,
it will be important to determine under
what circumstances IFNLR1 expression
may exceed the threshold required for
IRF1 induction. Furthermore, the observa-
tion that IFN-b, but not IFN-l, led to the
production of STAT1 homodimers, leading
to IRF1 induction, highlights the impor-
tance of non-canonical IFN signaling
pathways and suggests that such off-the-
diagram pathways may play an important
role in the distinct immune responses
elicited by type I versus type III IFNs.
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